The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Global Market Report 2025 indicates that the market size for PNH treatment has been experiencing rapid growth. In terms of value, the market is expected to rise from $5.35 billion in 2024 to an estimated $6.09 billion in 2025. This represents a compound annual growth rate (CAGR) of 13.8%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry?
The Paroxysmal Nocturnal Hemoglobinuria (PNH) treatment global market is expected to reach $10.09 billion by the year 2029. The market is also projected to grow at a compound annual growth rate (CAGR) of 13.5%.
Download Your Free Sample of the 2025 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
The key drivers in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market are:
• Rising prevalence of rare diseases
• Increased healthcare expenditure and accessibility to advanced therapies
• Growing investment in healthcare infrastructure
• Surge in home-based testing and remote monitoring activities
Global Market Segmentation: Identifying Major Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry Segments
The paroxysmal nocturnal hemoglobinuria (PNH) treatment market covered in this report is segmented –
1) By Treatment Type: Complement C5 Inhibitors, Anti-Complement Component 5a Receptor (C5aR) Monoclonal Antibodies, Alternative Pathway Inhibitors, Hematopoietic Stem Cell Transplantation, Other Therapies
2) By Route Of Administration: Intravenous, Subcutaneous, Oral
3) By market Availability: Approved, In Pipeline, Investigational
4) By End-Use: Hospitals, Specialty Clinics, Homecare Settings, Other End-Users
Pre-order the 2025 Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
The key trends in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market are:
• Advancements in genetic testing and biomarkers are actively shaping the future of the PNH treatment market.
• Novel therapies and their development are a significant emerging trend.
• The market is being heavily influenced by the rise in home-based testing and remote monitoring.
• Significant advancements in biotechnology and targeted therapies are a growing trend.
Who Are the Top Competitors & Leading Players in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
Major companies in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market are:
• F. Hoffmann-La Roche Ltd
• AstraZeneca PLC
• Novartis AG
• Amgen Inc.
• Mayo Clinic
• Regeneron Pharmaceuticals
• Cleveland Clinic Foundation
• Johns Hopkins Medicine
• Memorial Sloan Kettering Cancer Center
• Stanford Health Care
• University of California San Francisco (UCSF) Health
• Emory Healthcare
• Cedars-Sinai Medical Center
• Duke University Health System
• Mount Sinai Health System
• Dana-Farber Cancer Institute
• Swedish Orphan Biovitrum
• Alnylam Pharmaceuticals
• BioCryst Pharmaceuticals
• Apellis Pharmaceuticals
Regional Dominance: Which Area Leads the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market in 2024
